Sorrento Therapeutics, Inc. is a clinical‐stage biopharmaceutical company headquartered in San Diego, California, that specializes in developing therapies across oncology, immunology and pain management. Since its founding in 2009, the company has focused on advancing novel treatments leveraging its proprietary antibody discovery and engineering platforms. By applying cutting‐edge technologies, Sorrento seeks to address unmet medical needs in cancer and inflammatory diseases, with an expanding pipeline that includes antibody‐drug conjugates, targeted small molecules and cell therapies.
The company’s flagship G-MAB® antibody library platform underpins several of its clinical programs, enabling rapid identification of fully human monoclonal antibodies against tumor antigens. In oncology, lead candidates such as CD38‐targeting conjugates are being evaluated for multiple myeloma and other hematological malignancies. Sorrento has also built an immuno‐oncology portfolio around CAR‐T and CAR‐NK cell therapies aimed at solid tumors. Parallel to its cancer efforts, the company is developing non‐opioid pain therapeutics through its subsidiary Scilex®, with products designed to provide localized relief for post‐operative and chronic pain.
Beyond the United States, Sorrento pursues collaborations and partnerships in Europe and Asia, working with academic institutions and biopharmaceutical companies to expand its research reach and accelerate product development. Its Concentriq® platform supports rapid screening of antibody candidates, while Abivertinib®, an oral BTK and EGFR inhibitor, reflects the company’s commitment to small‐molecule innovation. Sorrento’s global footprint encompasses research operations in China, strategic alliances in Europe and a growing network of clinical trial sites across North America.
Under the leadership of founder, chairman and CEO Henry Ji, Ph.D., Sorrento has grown through targeted acquisitions and in‐licensing deals, bolstering its capabilities in immunotherapy and drug delivery. The company’s management team brings together experience in biotech research, clinical development and regulatory affairs, guiding Sorrento’s evolution from an antibody discovery start‐up to a multi‐platform biopharmaceutical enterprise. As Sorrento advances its pipeline through preclinical and clinical milestones, it continues to pursue strategic collaborations aimed at bringing its innovative therapies to patients worldwide.
AI Generated. May Contain Errors.
